Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Zoledronic acid, vitamin D, and calcium may prevent bone loss in patients who are
undergoing donor stem cell transplant.
PURPOSE: This randomized phase II trial is studying how well zoledronic acid works in
preventing osteoporosis in patients undergoing donor stem cell transplant.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute